AUTHORS
Ijeoma Julie Eche-Ugwu, PhD, MPH, FNP-BC, AOCNP, CPHON, TCT-CN, Christina Poh, MD2, Mark N Sorial, PharmD3, Patrick Connor Johnson, MD4, Kusha Chopra, BS5, Caroline T MacVicar, BS6, Alexandra W Lenart, BS7, Corben Yuwai Wong, BS8, Emma DeMarco, BS9, Riya Bhattacharjee, BS10, Xuan Cheng, BS11, Makoto Iwasaki, MD, PhD12, Fumiya Wada, MD, PhD13, Govind Bhagat, MD14, Valentina Nardi, MD15, Teresa Palomero, PhD16, Robert Willim, MD17, Meredith Nichols, MD18, Esther Rheinbay, PhD19, Eric Jacobsen, MD20, Enrica Marchi, MD, PhD21, Stefan K Barta, MD22, Carrie van der Weyden, MD23, Tatyana Feldman, MD24, Basem William, MD, MRCP(UK), FACP25, Estelle Verburgh, MD, PhD26, Nathan Lee Roberts, MD27, Danielle Blunt, MD28, Takashi Sakamoto, MD, PhD29, Yumeng Zhang, MD30, Bradley Haverkos, MD31, Mitsumasa Watanabe, MD32, Nora Bennani, MD33, Yun Kyoung Tiger, MD, PhD34, Jonathan Brammer, MD35, Pamela Allen, MD36, Deepa Jagadeesh, MD, MPH37, Maya deepti Srinivasan, MD, MSc38, John Mark L Sloan Jr, MD39, Lauren Shea, MD40, Harsh Rohit Shah, DO41, Sonali Smith, MD, FASCO42, Nazila Shafagati, MD43, Bhagirathbhai Dholaria, MD, FACP44, Salvia Jain, MD45
AFFILIATIONS
1 Dana-Farber Cancer Insitute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
4 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
5 MGH, Boston, Massachusetts, United States
6 MGH, Boston, Massachusetts, United States
7 MGH, Boston, Massachusetts, United States
8 MGH, Boston, Massachusetts, United States
9 MGH, Boston, Massachusetts, United States
10 MGH, Boston, Massachusetts, United States
11 MGH, Boston, Massachusetts, United States
12 MGH, Boston, Massachusetts, United States
13 Kyoto University Hospital, Kyoto, Japan
14 Saint Louis University School of Medicine, Saint Louis, Montana, United States
15 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
16 Columbia University Medical Center, NY, New York, United States
17 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
18 Cleveland Clinic, Cleveland, Ohio, United States
19 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
20 Dana-Farber Cancer Insitute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
21 Dana-Farber Cancer Insitute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
22 University of Pennsylvania, Philadelphia, Pennsylvania, United States
23 Peter MacCallum Cancer Center, Melbourne, Australia
24 Hackensack Meridian Health Network, NJ, United States
25 OhioHealth, Columbus, United States
26 University of Cape town, Capetown, South Africa
27 University of Virginia Cancer Center, Charlottsville, United States
28 Royal Adelaide Hospital, Adelaide, Australia
29 Kyoto University Hospital, Kyoto, Japan
30 Moffitt Cancer Center, Tampa, United States
31 University of Colorada, Denver, United States
32 Amagasaki General Medical Center, Amagasaki, Japan
33 Mayo Clinic, Rochester, United States
34 Mayo Clinic, Rochester, United States
35 Ohio State University Wexner, Columbus, United States
36 Emory University, Atlanta, United States
37 Cleveland Clinic, Columbus, United States
38 Boston Medical Center, Boston, Massachusetts, United States, Boston Medical Center, Boston, Massachusetts, United States, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
39 Boston Medical Center, Boston, Massachusetts, United States
40 University of Alabama at Birmingham Medical Center, Alabama, United States
41 Huntsman Cancer Institute, Utah, United States
42 University of Chicago, Chicago, United States
43 University of Chicago, Chicago, United States
44 Vanderbilt University Medical Center, Nashville, United States
45 Harvard Medical School, Boston, Massachusetts, United States, MGH, Boston, Massachusetts, United States
ABSTRACT
Introduction
Despite growing recognition of the importance of patient-reported outcomes in oncology, health-related quality of life (HRQOL) among patients with PTCL remains poorly characterized, and the modifiable factors that contribute to HRQOL impairments in this population are not well understood. This knowledge gap limits the field's ability to identify patients at greatest risk for poor HRQOL and to design targeted supportive interventions. Therefore, we sought to characterize the association between distress and patient-reported HRQOL among patients with PTCL.
Methods
We conducted a cross-sectional analysis using baseline, pre-treatment data from patients with various PTCL subtypes that were prospectively enrolled in the PETAL Consortium beginning in (January/2024) across 17 academic centers in 4 continents. HRQOL and its subscale scores were assessed using the Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym-42) and summarized using descriptive statistics. Psychological distress was assessed using the Hospital Anxiety and Depression Scale (HADS-14), comprising two 7-item subscales measuring anxiety (HADS-A) and depression (HADS-D). Linear regression models, adjusted for potential confounders, were used to examine the association between distress (anxiety and depression) and HRQOL. Clinically significant anxiety and depression were defined as HADS-A or HADS-D scores ≥8, respectively, and each was analyzed as a dichotomous variable (present vs. absent).
Results
Of the 120 participants with complete HRQOL and demographic data, the median age was 65 years (range, 19.7–85.9). Most participants were male (62.5%), white (75.6%), non-Hispanic (98.3%), married or partnered (79%), and employed (44.1%). The majority (85.8%) had an ECOG performance status of 0-1, and 94 (78.3%) were newly diagnosed with PTCL. The median time from diagnosis to enrollment was 13.2 months (range, 1.7-151.4). In univariate models, white race was associated with higher HRQOL scores (β = 11.1; 95% CI: 0.56–21.7; p = 0.039), whereas ECOG performance status ≥2 was associated with lower HRQOL scores (β = −23.6; 95% CI: −36.2 to −11.1; p < 0.001). Sex, age, marital status, employment status, and diagnosis recency were not significantly associated with HRQOL. The mean total HRQOL score was 119.7 (SD: 25.4; median: 125.5; IQR: 101.5-139; range, 48–166). Mean subscale scores were as follows: Physical Well-Being, 19.9 (SD: 6.4); Social/Family Well-Being, 22.9 (SD: 5.4); Emotional Well-Being, 17.2 (SD: 4.4); Functional Well-Being, 16.5 (SD: 6.5); and Lymphoma-Specific Concerns, 42.9 (SD: 9.8). Mean anxiety and depression scores were 6.4 (SD: 4.1; range, 0–17) and 5.1 (SD: 4.0; range, 0–16), respectively. Participants with clinically significant anxiety had a lower mean total HRQOL score than those without (101.5 [SD: 3.1] vs. 130.0 [SD: 2.3]; mean difference [MD] = −28.4; 95% CI: −36.4 to −20.5; p < 0.001). Similarly, participants with clinically significant depressive symptoms had a lower mean total HRQOL score than those without (93.4 [SD: 3.4] vs. 129.1 [SD: 2.0]; MD = −35.6; 95% CI: −43.6 to −27.6; p < 0.001). Both anxiety and depressive symptoms were associated with significantly lower scores across FACT-Lym subscales, with the largest differences observed for the Lymphoma-Specific Concerns subscale (anxiety: MD = −10.4; 95% CI: −13.6 to −7.2; p < 0.001; depression: MD = −13.4; 95% CI: −16.7 to −10.1; p < 0.001).
Conclusions
To our knowledge, this is among the first prospective studies to characterize baseline patient-reported quality of life in patients with PTCL. In this interim analysis of the PETAL consortium cohort, patients with PTCL reported HRQOL comparable to that observed in other lymphoma populations. Anxiety and depressive symptoms were strongly and consistently associated with inferior pre-treatment HRQOL, particularly within lymphoma-specific concerns. Given the rarity of PTCL and the limited data available on parent-reported outcomes in this population, these findings underscore that routine psychological distress screening and early integration of psychosocial support may represent a critical, underutilized strategy to improve quality of life. Future longitudinal studies are needed to evaluate HRQOL trajectories and inform the development of targeted supportive care interventions.
DISCLOSURES
Ijeoma Julie Eche-Ugwu, PhD, MPH, FNP-BC, AOCNP, CPHON, TCT-CN: No relevant conflicts of interest to declare.